Gabritab 50-AT Tablet is a combination medication containing Amitriptyline 10mg and Pregabalin 50mg, primarily used for the management of neuropathic pain and certain mood disorders. Amitriptyline, a tricyclic antidepressant, works by modulating neurotransmitters in the brain, helping to alleviate symptoms of depression and chronic pain. Pregabalin, an anticonvulsant and analgesic agent, reduces nerve pain by calming overactive nerve signals. Together, these active ingredients provide a synergistic effect, making Gabritab 50-AT effective in treating conditions such as diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and generalized anxiety disorder. The tablet is usually prescribed when monotherapy is insufficient, offering enhanced pain relief and mood stabilization. Patients should take Gabritab 50-AT exactly as directed by a healthcare professional, typically once or twice daily, with or without food. Common side effects may include dizziness, drowsiness, dry mouth, and weight gain, while more serious reactions require immediate medical attention. It is important to inform the doctor of any existing medical conditions, allergies, or concurrent medications to avoid adverse interactions. Gabritab 50-AT should not be discontinued abruptly to prevent withdrawal symptoms. Regular follow-up is recommended to monitor efficacy and safety during treatment.